www.fdanews.com/articles/178694-somahlution-reveals-positive-study-results-showing-efficacy-of-duragraft
Somahlution Reveals Positive Study Results Showing Efficacy of DuraGraft
October 4, 2016
Somahlution’s DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery, the company said at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting.
DuraGraft treatment for 2,436 patients who underwent CABG surgery has shown statistically significant lower risks for non-fatal myocardial infarction, repeat revascularization, and a composite of all major adverse cardiac events.
DuraGraft is currently not available in the U.S. market. — Cynthia Jessup